Phase I Metabolism
Phase I Metabolism - Related Videos
01:17
Drug Metabolism: Phase I Reactions
0 Views •
2023
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
01:14
Drug Metabolism: Phase II Reactions
0 Views •
2023
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
0 Views •
2017
Metabolic competency of in vitro systems is a key requirement for the biotransformation and disposition of drugs and toxicants. In this protocol, we describe the application of reference metabolic probes to assess phase I metabolism in cell cultures.
05:41
Metabolic Profile Analysis of Zebrafish Embryos
0 Views •
Cited by 42 •
2013
Zebrafish represent a powerful vertebrate model that has been under-utilised for metabolic studies. Here we describe a rapid way to measure the in vivo metabolic profile of developing zebrafish that allows the comparison of different mitochondrial function parameters between genetically or pharmacologically manipulated embryos, thereby increasing the applicability of this organism.
08:28
Metabolic Labeling
0 Views •
2023
Metabolic labeling is used to probe the biochemical transformations and modifications that occur in a cell. This is accomplished by using chemical analogs that mimic the structure of natural biomolecules. Cells utilize analogs in their endogenous biochemical processes, producing compounds that are labeled. The label allows for the incorporation of detection and affinity tags, which can then be used to elucidate metabolic pathways using other biochemical analytical techniques, such as SDS-PAGE...
FAQs
Different reaction types can produce different clinical consequences. Oxidation by cytochrome P450 enzymes, along with reduction and hydrolysis by other enzymes, may inactivate a compound, activate a prodrug, or create a reactive metabolite. Thus, the same metabolic stage can decrease drug effect, enable therapeutic activity, or increase toxicity, depending on the chemical product formed.
Introducing or exposing a functional group changes the chemical properties of a drug or foreign compound. This modification can alter its activity and solubility, which in turn influences how the body handles and eliminates it. The chemical change therefore provides a mechanistic link between enzyme-catalyzed transformation and clinically relevant differences in drug behavior.
Enzyme inhibition and induction can change the extent or speed of Phase I transformation. Inhibition may reduce the metabolism of a compound, whereas induction may increase the system’s metabolic capacity. These changes can modify drug activity, elimination, or the formation of metabolites, making enzyme effects an important source of clinically relevant drug interactions.
The liver is a primary site of Phase I metabolism, so liver disease can affect the body’s capacity to chemically modify drugs. Patients also differ in metabolic capacity even without recognized liver disease. These variations can change pharmacokinetics and support the need for safer, individualized dosing strategies rather than assuming that one dose has the same consequences for everyone.
Clinicians consider which Phase I pathways modify a medication, whether the resulting product is active or inactive, and whether reactive metabolites may form. This information helps them predict pharmacokinetics, anticipate altered drug handling, and recognize situations in which enzyme effects or reduced liver function could make a dosing strategy less safe.
Assessment is especially important when a medication depends on enzyme-mediated transformation, can produce a reactive metabolite, or is given to a patient with altered metabolic capacity. It also matters when enzyme inhibition or induction may cause a drug interaction. In these settings, understanding the pathway supports safer dose selection and helps clinicians anticipate changes in drug activity or toxicity.